Trung Huynh
Stock Analyst at RBC Capital
(4.45)
# 208
Out of 5,182 analysts
64
Total ratings
60%
Success rate
19.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Reiterates: Underperform | $25 | $26.79 | -6.68% | 8 | Apr 20, 2026 | |
| MRK Merck & Co. | Reiterates: Outperform | $142 | $110.23 | +28.82% | 6 | Mar 30, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $868.27 | +43.96% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $57.78 | +3.84% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $197.38 | +31.73% | 2 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $744.44 | -11.34% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $135.98 | +63.99% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $0.93 | +2,588.46% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $340.18 | -6.81% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $33.66 | +12.89% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $2.91 | +140.55% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.99 | +44.61% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $225.34 | -22.34% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.13 | - | 1 | Mar 23, 2021 |
Pfizer
Apr 20, 2026
Reiterates: Underperform
Price Target: $25
Current: $26.79
Upside: -6.68%
Merck & Co.
Mar 30, 2026
Reiterates: Outperform
Price Target: $142
Current: $110.23
Upside: +28.82%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $868.27
Upside: +43.96%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $57.78
Upside: +3.84%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $197.38
Upside: +31.73%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $744.44
Upside: -11.34%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $135.98
Upside: +63.99%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $0.93
Upside: +2,588.46%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $340.18
Upside: -6.81%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $33.66
Upside: +12.89%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.91
Upside: +140.55%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $8.99
Upside: +44.61%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $225.34
Upside: -22.34%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.13
Upside: -